ANALYSIS OF PHARMACOTHERAPY OF ARTERIAL HYPERTENSION BASED ON RESULTS OF PIFAGOR III STUDY

The article presents the results of pharmacoepidemiological study of arterial hypertension (AH) in Russia PIFAGOR III. 3030 valid questionnaires completed by patients with AH (63% men, 35% women) were analyzed. The mean age of patients was 58.3 years (from 20 to 95 years). 79% of patients regularly use antihypertensive drugs (AHD), the mean number of used AHD - 2,22 per 1 patient. Distribution of AHD by classes: angiotensin converting enzyme inhibitors (ACEI) - 33.2%, β-blockers - 20.3%, diuretics - 19.7%, calcium channel blockers - 13.4%, angiotensin-2 receptor antagonists - 3.1% , central acting drugs - 2.9%. In the group of ACE inhibitors, 3 drugs dominate: enalapril (44%), lisinopril (15%), perindopril (10.3%). In the group of β-blockers, bisoprolol (41,3%) and metoprolol (27,5%) are often used. In the group of diuretics, 67.0% was accounted for indapamide, 23.7% - hydrochlorothiazide. Amlodipine (53.4%) take the lead in the group of calcium channel blockers. Among the central acting drugs, clonidine share is 28%, rezerpine-containing drugs - 31%, and moxonidine - 32%. Overall, 161 brand-name drugs are used by patients, and only 39% of AHD are innovator drugs. The motivation and treatment compliance have increased: 83% of patients controls blood pressure (BP) at home, 16% - attends AH school, and 69% of patients have target BP levels. The positive trends in the quality and effectiveness of pharmacotherapy of AH are revealed. However, problems of provision and availability of different AHD for patients are not resolved.

arterial hypertension, pharmacoepidemiological study, antihypertensive therapy